Sangamo Therapeutics (NASDAQ:SGMO) Posts Earnings Results, Misses Expectations By $0.12 EPS

Sangamo Therapeutics (NASDAQ:SGMO) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.12), reports. Sangamo Therapeutics had a negative net margin of 331.28% and a negative return on equity of 813.95%. The company had revenue of $14.23 million during the quarter, compared to analyst estimates of $40.25 million.

Here are the key takeaways from Sangamo Therapeutics’ conference call:

• Rolling BLA submission is underway for ST-920 with the clinical and non-clinical modules submitted, the companion diagnostic accepted by CDRH, process validation and method validation completed, and a first commercial lot manufactured, supported by a positive mean annualized eGFR slope that the FDA said could support accelerated approval.
• Sangamo repeatedly warned the BLA completion and broader operations are contingent on securing additional funding and a Fabry commercialization partner, noting limited cash resources despite raising >$130M in 2025 and managing spend to extend runway.
• The company has transitioned into a clinical-stage neurology company—ST-503 received Fast Track designation, six sites are active in the Phase I/II STAND study, and preclinical ST-503 data were published in Science Translational Medicine; ST-506 CTA-enabling work and GLP toxicology are also progressing.
• Sangamo emphasized continued external validation of its STAC-BBB capsid platform, announcing a third neurology capsid license (with Eli Lilly) and generating non-dilutive license fees and milestone payments as part of >$130M of 2025 funding.

Sangamo Therapeutics Stock Performance

SGMO opened at $0.31 on Tuesday. The stock has a market capitalization of $103.40 million, a PE ratio of -0.70 and a beta of 1.33. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $0.84. The business’s 50 day moving average price is $0.39 and its 200 day moving average price is $0.48.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SGMO. Cetera Investment Advisers acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $31,000. XTX Topco Ltd acquired a new stake in shares of Sangamo Therapeutics during the 2nd quarter worth about $41,000. State of Wyoming acquired a new stake in shares of Sangamo Therapeutics during the 4th quarter worth about $47,000. Engineers Gate Manager LP raised its holdings in Sangamo Therapeutics by 101.7% in the 2nd quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 44,078 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Sangamo Therapeutics in the 4th quarter valued at about $56,000. Hedge funds and other institutional investors own 56.92% of the company’s stock.

Sangamo Therapeutics News Roundup

Here are the key news stories impacting Sangamo Therapeutics this week:

• Positive Sentiment: Positive registrational Fabry results and rolling BLA — Sangamo reported positive topline STAAR study data (mean annualized eGFR slope at 52 weeks) and says a rolling BLA to the FDA for ST-920 is in progress; the FDA previously indicated the eGFR slope could serve as primary basis for Accelerated Approval. Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
• Positive Sentiment: BLA timing and regulatory path — Management is targeting a summer 2026 BLA submission for Fabry (ST-920), giving investors a near-term regulatory milestone to watch that could materially re-rate the stock if accepted. Sangamo targets summer 2026 for Fabry BLA submission while advancing neurology pipeline and partner talks
• Positive Sentiment: Neurology expansion, partnerships and funding — Sangamo has transitioned to a clinical-stage neurology effort (STAND study sites active), struck a third neurology capsid license with Eli Lilly, and raised >$130M in 2025 from license fees, milestones and equity — these deals improve runway and de-risk near-term financing. Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
• Neutral Sentiment: Earnings call and strategic commentary — Management reiterated strategic advances on the call and provided pipeline updates; the transcript and highlights give detail for investors assessing timelines and risks. Sangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and …
• Negative Sentiment: Q4 results missed expectations — Sangamo reported ($0.11) EPS vs. $0.01 consensus and revenue of $14.23M vs. ~$40M expected; the miss, large negative margins and weak guidance led to premarket selling and pressure on the stock. Why PEPG, SGMO, PHR are among top premarket losers today

Analyst Ratings Changes

Several analysts have issued reports on SGMO shares. Wall Street Zen cut Sangamo Therapeutics to a “strong sell” rating in a report on Saturday, January 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of Sangamo Therapeutics in a research report on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, February 10th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Sangamo Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $5.50.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.